Trial Profile
A Phase II Study of Second-Line Therapy With Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 15 Mar 2019 Status changed from active, no longer recruiting to discontinued.
- 02 Feb 2018 Planned End Date changed from 1 Mar 2019 to 1 Sep 2019.
- 17 Jul 2017 Planned End Date changed from 1 Sep 2018 to 1 Mar 2019.